ATRIA Bleeding Risk Score
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low0–3
- Intermediate4–4
- High5–10
The ATRIA Bleeding Risk Score calculates stratifying cardiovascular risk, predicting thromboembolic events, or guiding therapeutic interventions. Key inputs include anemia. Scores guide initiating guideline-directed medical therapy, antithrombotic or anticoagulant regimens, or urgent coronary angiography. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Determines bleeding risk for patients on warfarin therapy for atrial fibrillation. The score was developed and validated in the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) cohort and helps stratify patients into low, intermediate, and high risk categories for major hemorrhage.
Clinical Indication
The ATRIA Bleeding Risk Score is indicated for bedside clinical practice to support Determines bleeding risk for patients on warfarin therapy for atrial fibrillation. The score was developed and validated in the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) cohort and helps stratify patients into low, intermediate, and high risk categories for major hemorrhage.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Adult patients presenting with suspected or established coronary artery disease, cardiac arrhythmias, congestive heart failure, or valvular heart defects. Clinical application is indicated across Emergency department, cardiac care unit (CCU), cardiac catheterization laboratory, and outpatient cardiology clinics.
Limitations & Contraindications
In hemodynamically unstable cardiogenic shock, cardiac arrest, or refractory acute coronary syndromes, immediate resuscitation and coronary angiography supersede scoring. Clinical exclusion: Patients with a history of intracranial hemorrhage were likely excluded from the development cohort..
Clinical Pearls & Action Plan
Continuous 12-lead ECG monitoring, serial cardiac troponin measurements, and echocardiographic evaluation align with ESC/ACC/AHA clinical practice guidelines.
ATRIA Score = Anemia (3 points) + Severe Renal Disease (3 points) + Age ≥75 (2 points) + Prior Hemorrhage (1 point) + Hypertension (1 point)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| anemia | string | Yes | Presence of anemia (Hemoglobin <13 g/dL in males or <12 g/dL in females) |
| severe_renal_disease | string | Yes | Severe renal disease (GFR <30 mL/min or dialysis-dependent) |
| age_75_or_over | string | Yes | Age ≥75 years |
| prior_hemorrhage | string | Yes | Any prior hemorrhage diagnosis (e.g., GI bleed, intracranial hemorrhage) |
| hypertension | string | Yes | History of hypertension |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–3 | Low | Low bleeding risk |
| 4–4 | Intermediate | Intermediate bleeding risk |
| 5–10 | High | High bleeding risk |
Evidence-Based References (EBM)
- Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011 Jul 19;58(4):395-401. doi: 10.1016/j.jacc.2011.03.031.DOI: 10.1016/j.jacc.2011.03.031
- Roldán V, Marín F, Fernández H, Manzano-Fernández S, Gallego P, Valdés M, et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. Chest. 2013 Jan;143(1):179-184. doi: 10.1378/chest.12-0608.DOI: 10.1378/chest.12-0608
- Senoo K, Proietti M, Lane DA, Lip GY. Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. Am J Med. 2016 Jun;129(6):600-7. doi: 10.1016/j.amjmed.2015.10.001.DOI: 10.1016/j.amjmed.2015.10.001